Publication

Towards precision medicine in ANCA-associated vasculitis

van der Geest, K. S. M., Brouwer, E., Sanders, J-S., Sandovici, M., Bos, N. A., Boots, A. M. H., Abdulahad, W. H., Stegeman, C. A., Kallenberg, C. G. M., Heeringa, P. & Rutgers, A., Aug-2018, In : Rheumatology. 57, 8, p. 1332-1339 8 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard

Documents

  • Towards precision medicine in ANCA-associated vasculitis

    Final publisher's version, 252 KB, PDF-document

DOI

ANCA-associated vasculitis (AAV) is characterized by inflammation and destruction of small and medium-sized vessels. Current management strategies for AAV have been validated in large groups of patients. However, recent insights indicate that distinct patient subsets may actually exist within AAV, thereby justifying the development of more personalized treatment strategies. In this review, we discuss current evidence for a better classification of AAV based on ANCA type. We describe how thus defined categories of AAV patients may differ in genetic background, clinical presentation, immune pathology, response to treatment and disease outcome. We also explore how these insights may provide a rationale for targeted treatments in different categories of AAV patients. Finally, we provide recommendations on how to further establish precision medicine in AAV.

Original languageEnglish
Pages (from-to)1332-1339
Number of pages8
JournalRheumatology
Volume57
Issue number8
Early online date17-Oct-2017
Publication statusPublished - Aug-2018

    Keywords

  • disease subsets, vasculitis, ANCA, precision medicine, personalized medicine, ANTIBODY-ASSOCIATED VASCULITIS, ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES, NEUTROPHIL EXTRACELLULAR TRAPS, SMALL-VESSEL VASCULITIS, NECROSIS-FACTOR-ALPHA, WEGENERS-GRANULOMATOSIS, T-CELLS, TREATMENT RESISTANCE, RENAL VASCULITIS, EOSINOPHILIC GRANULOMATOSIS

View graph of relations

ID: 49235396